instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Meningoencephalitis viral'. | Enteroviral Meningoencephalitis as a Complication of Rituximab Therapy for Rheumatoid Arthritis.
Enteroviral meningoencephalitis is a rare complication of rituximab therapy that has been described in the treatment of hematologic malignancies. We report the first case of enteroviral meningoencephalitis in a patient rece... | HYDROXYCHLOROQUINE, LEFLUNOMIDE, METHOTREXATE, RITUXIMAB | DrugsGivenReaction | CC BY | 34707960 | 20,236,436 | 2021-09 |
What was the outcome of reaction 'Encephalitis'? | Enteroviral Meningoencephalitis as a Complication of Rituximab Therapy for Rheumatoid Arthritis.
Enteroviral meningoencephalitis is a rare complication of rituximab therapy that has been described in the treatment of hematologic malignancies. We report the first case of enteroviral meningoencephalitis in a patient rece... | Recovered | ReactionOutcome | CC BY | 34707960 | 20,314,936 | 2021-09 |
What was the outcome of reaction 'Meningoencephalitis viral'? | Enteroviral Meningoencephalitis as a Complication of Rituximab Therapy for Rheumatoid Arthritis.
Enteroviral meningoencephalitis is a rare complication of rituximab therapy that has been described in the treatment of hematologic malignancies. We report the first case of enteroviral meningoencephalitis in a patient rece... | Recovered | ReactionOutcome | CC BY | 34707960 | 20,236,436 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug intolerance'. | Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review.
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in h... | HYDROXYUREA, RUXOLITINIB | DrugsGivenReaction | CC BY | 34707996 | 20,240,205 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review.
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in h... | HYDROXYUREA, RUXOLITINIB | DrugsGivenReaction | CC BY | 34707996 | 20,240,205 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Splenomegaly'. | Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review.
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in h... | HYDROXYUREA, RUXOLITINIB | DrugsGivenReaction | CC BY | 34707996 | 20,240,205 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review.
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in h... | HYDROXYUREA, RUXOLITINIB | DrugsGivenReaction | CC BY | 34707996 | 20,240,205 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bradycardia'. | A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil.
Brugada syndrome (BrS) is an inherited disorder associated with increased risk of ventricular arrhythmias and sudden cardiac death. The most common genetic alteration is a loss of function mutation of SCN5A gene.... | FLECAINIDE, METOPROLOL | DrugsGivenReaction | CC BY-NC | 34708182 | 19,460,716 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Brugada syndrome'. | A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil.
Brugada syndrome (BrS) is an inherited disorder associated with increased risk of ventricular arrhythmias and sudden cardiac death. The most common genetic alteration is a loss of function mutation of SCN5A gene.... | FLECAINIDE | DrugsGivenReaction | CC BY-NC | 34708182 | 20,079,981 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil.
Brugada syndrome (BrS) is an inherited disorder associated with increased risk of ventricular arrhythmias and sudden cardiac death. The most common genetic alteration is a loss of function mutation of SCN5A gene.... | FLECAINIDE, METOPROLOL | DrugsGivenReaction | CC BY-NC | 34708182 | 19,460,716 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Electrocardiogram abnormal'. | A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil.
Brugada syndrome (BrS) is an inherited disorder associated with increased risk of ventricular arrhythmias and sudden cardiac death. The most common genetic alteration is a loss of function mutation of SCN5A gene.... | FLECAINIDE, METOPROLOL | DrugsGivenReaction | CC BY-NC | 34708182 | 19,460,716 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Unmasking of previously unidentified disease'. | A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil.
Brugada syndrome (BrS) is an inherited disorder associated with increased risk of ventricular arrhythmias and sudden cardiac death. The most common genetic alteration is a loss of function mutation of SCN5A gene.... | FLECAINIDE ACETATE | DrugsGivenReaction | CC BY-NC | 34708182 | 19,318,700 | 2021-03 |
What was the outcome of reaction 'Brugada syndrome'? | A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil.
Brugada syndrome (BrS) is an inherited disorder associated with increased risk of ventricular arrhythmias and sudden cardiac death. The most common genetic alteration is a loss of function mutation of SCN5A gene.... | Recovered | ReactionOutcome | CC BY-NC | 34708182 | 20,079,981 | 2021-03 |
What was the outcome of reaction 'Unmasking of previously unidentified disease'? | A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil.
Brugada syndrome (BrS) is an inherited disorder associated with increased risk of ventricular arrhythmias and sudden cardiac death. The most common genetic alteration is a loss of function mutation of SCN5A gene.... | Recovered | ReactionOutcome | CC BY-NC | 34708182 | 19,318,700 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial.
BACKGROUND
To compare the efficacy and tolerability of dapagliflozin with those of sitagliptin and metformin in patients with type 2 diabetes... | METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC | 34709582 | 20,206,661 | 2021-12 |
What was the outcome of reaction 'Diarrhoea'? | Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial.
BACKGROUND
To compare the efficacy and tolerability of dapagliflozin with those of sitagliptin and metformin in patients with type 2 diabetes... | Recovered | ReactionOutcome | CC BY-NC | 34709582 | 20,206,661 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abnormal loss of weight'. | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | ERYTHROPOIETIN, HYDROXYCHLOROQUINE, LOSARTAN, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, PREDNISOLONE, RITUXIMAB, TACROLIMUS | DrugsGivenReaction | CC BY-NC | 34712442 | 19,043,022 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Normochromic normocytic anaemia'. | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | ERYTHROPOIETIN, HYDROXYCHLOROQUINE, LOSARTAN, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, PREDNISOLONE, RITUXIMAB, TACROLIMUS | DrugsGivenReaction | CC BY-NC | 34712442 | 19,043,022 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rectal polyp'. | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | ERYTHROPOIETIN, HYDROXYCHLOROQUINE, LOSARTAN, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, PREDNISOLONE, RITUXIMAB, TACROLIMUS | DrugsGivenReaction | CC BY-NC | 34712442 | 19,043,022 | 2021-01 |
What was the administration route of drug 'ERYTHROPOIETIN'? | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34712442 | 19,000,422 | 2021-01 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC | 34712442 | 19,000,422 | 2021-01 |
What was the dosage of drug 'RITUXIMAB'? | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC | 34712442 | 19,000,422 | 2021-01 |
What was the outcome of reaction 'Abnormal loss of weight'? | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | Recovering | ReactionOutcome | CC BY-NC | 34712442 | 19,043,022 | 2021-01 |
What was the outcome of reaction 'Malacoplakia gastrointestinal'? | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | Recovering | ReactionOutcome | CC BY-NC | 34712442 | 19,000,422 | 2021-01 |
What was the outcome of reaction 'Normochromic normocytic anaemia'? | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | Recovering | ReactionOutcome | CC BY-NC | 34712442 | 19,043,022 | 2021-01 |
What was the outcome of reaction 'Rectal polyp'? | Malakoplakia as a Rare Cause of Diarrhea: Case Presentation and Review of Literature.
Colonic malakoplakia is a rare chronic granulomatous disease that can involve many organs such as the lung, brain, pancreas, bone, adrenal glands, and genitourinary tract. The most common site of involvement outside the genitourinary ... | Recovering | ReactionOutcome | CC BY-NC | 34712442 | 19,043,022 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated intravascular coagulation'. | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | HEPARIN SODIUM, HYDROXYCHLOROQUINE SULFATE, INTERFERON BETA, LOPINAVIR\RITONAVIR, MORPHINE SULFATE, ONDANSETRON, RIBAVIRIN | DrugsGivenReaction | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | HEPARIN SODIUM, HYDROXYCHLOROQUINE SULFATE, INTERFERON BETA, LOPINAVIR\RITONAVIR, MORPHINE SULFATE, ONDANSETRON, RIBAVIRIN | DrugsGivenReaction | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | HEPARIN SODIUM, HYDROXYCHLOROQUINE SULFATE, INTERFERON BETA, LOPINAVIR\RITONAVIR, MORPHINE SULFATE, ONDANSETRON, RIBAVIRIN | DrugsGivenReaction | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | HEPARIN SODIUM, HYDROXYCHLOROQUINE SULFATE, INTERFERON BETA, LOPINAVIR\RITONAVIR, MORPHINE SULFATE, ONDANSETRON, RIBAVIRIN | DrugsGivenReaction | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
What was the administration route of drug 'ONDANSETRON'? | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
What was the dosage of drug 'HYDROXYCHLOROQUINE SULFATE'? | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | 400 mg (milligrams). | DrugDosage | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
What was the dosage of drug 'INTERFERON BETA'? | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | 250 µg (micrograms). | DrugDosage | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
What was the dosage of drug 'LOPINAVIR\RITONAVIR'? | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | 100/400MG | DrugDosageText | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
What was the dosage of drug 'RIBAVIRIN'? | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | 1200 mg (milligrams). | DrugDosage | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
What was the outcome of reaction 'Disseminated intravascular coagulation'? | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | Fatal | ReactionOutcome | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
What was the outcome of reaction 'Sepsis'? | Intestinal Ischemia Due to Mesenteric Vascular Thrombosis in a Patient with Positive SARS-Cov-2 RNA without Primary Pulmonary Symptom: A Case Report.
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus SARS-CoV-2. The clinical manifestations of this infection have a range and... | Fatal | ReactionOutcome | CC BY-NC | 34712443 | 19,030,088 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatitis cholestatic'. | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34712676 | 20,091,622 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34712676 | 20,091,622 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34712676 | 20,091,622 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory failure'. | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34712676 | 20,091,622 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | LEVOFLOXACIN, MEROPENEM, METHYLPREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 34712676 | 20,569,520 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Underdose'. | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34712676 | 20,091,622 | 2021 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | 80 MG | DrugDosageText | CC BY | 34712676 | 20,569,520 | 2021 |
What was the outcome of reaction 'Hepatitis cholestatic'? | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | Recovered | ReactionOutcome | CC BY | 34712676 | 20,091,622 | 2021 |
What was the outcome of reaction 'Pneumonia'? | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | Recovered | ReactionOutcome | CC BY | 34712676 | 20,091,622 | 2021 |
What was the outcome of reaction 'Respiratory failure'? | Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
Background: Immune checkpoint inhibitors have provided significant clinical benefits to many patients with advanced cancer; however, severe immune-related adv... | Recovered | ReactionOutcome | CC BY | 34712676 | 20,091,622 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aneurysm ruptured'. | A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.
BACKGROUND
Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing aw... | BISOPROLOL, PAZOPANIB, WARFARIN | DrugsGivenReaction | CC BY | 34713631 | 20,056,588 | 2021-10-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Splenic artery aneurysm'. | A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.
BACKGROUND
Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing aw... | BISOPROLOL, PAZOPANIB, WARFARIN | DrugsGivenReaction | CC BY | 34713631 | 20,056,588 | 2021-10-28 |
What was the outcome of reaction 'Aneurysm ruptured'? | A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.
BACKGROUND
Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing aw... | Recovered | ReactionOutcome | CC BY | 34713631 | 20,056,588 | 2021-10-28 |
What was the outcome of reaction 'Splenic artery aneurysm'? | A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.
BACKGROUND
Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing aw... | Recovered | ReactionOutcome | CC BY | 34713631 | 20,056,588 | 2021-10-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic cytolysis'. | Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report.
BACKGROUND
Alectinib is a tyrosine kinase inhibitor (TKI) approved for use as first-line metastatic therapy for patients with anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Certain me... | ALECTINIB, AMIODARONE | DrugsGivenReaction | CC BY | 34713842 | 20,435,766 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypothyroidism'. | Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report.
BACKGROUND
Alectinib is a tyrosine kinase inhibitor (TKI) approved for use as first-line metastatic therapy for patients with anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Certain me... | ALECTINIB, AMIODARONE | DrugsGivenReaction | CC BY | 34713842 | 20,435,766 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional product misuse'. | Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report.
BACKGROUND
Alectinib is a tyrosine kinase inhibitor (TKI) approved for use as first-line metastatic therapy for patients with anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Certain me... | ALECTINIB, AMIODARONE | DrugsGivenReaction | CC BY | 34713842 | 20,435,766 | 2021-10-29 |
What was the dosage of drug 'ALECTINIB'? | Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report.
BACKGROUND
Alectinib is a tyrosine kinase inhibitor (TKI) approved for use as first-line metastatic therapy for patients with anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Certain me... | 8 DOSAGE FORM, ONCE A DAY(8 DOSAGE FORMS DAILY; INITIALLY, ADMINISTERED VIA NASOGASTRIC FEEDING TUBE | DrugDosageText | CC BY | 34713842 | 20,435,766 | 2021-10-29 |
What was the outcome of reaction 'Hepatic cytolysis'? | Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report.
BACKGROUND
Alectinib is a tyrosine kinase inhibitor (TKI) approved for use as first-line metastatic therapy for patients with anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Certain me... | Recovering | ReactionOutcome | CC BY | 34713842 | 20,435,766 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alanine aminotransferase increased'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aspartate aminotransferase increased'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dysgeusia'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Giant cell tumour of tendon sheath'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemoglobin decreased'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hair colour changes'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyponatraemia'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypophosphataemia'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphocyte count decreased'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutrophil count decreased'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Periorbital oedema'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Platelet count decreased'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Primary biliary cholangitis'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product dose omission issue'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pruritus'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy partial responder'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Transaminases increased'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment noncompliance'. | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
OBJECTIVE
To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulati... | DENOSUMAB, SIROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34716196 | 20,478,576 | 2021-10-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34716205 | 20,601,177 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chills'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD | DrugsGivenReaction | CC BY-NC | 34716205 | 20,609,820 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Constipation'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34716205 | 20,601,177 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | TEMOZOLOMIDE | DrugsGivenReaction | CC BY-NC | 34716205 | 20,645,899 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | TEMOZOLOMIDE | DrugsGivenReaction | CC BY-NC | 34716205 | 20,620,883 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gingival bleeding'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34716205 | 20,768,929 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gingival discomfort'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34716205 | 20,768,929 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Influenza like illness'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34716205 | 20,768,929 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | TEMOZOLOMIDE | DrugsGivenReaction | CC BY-NC | 34716205 | 20,620,883 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral discomfort'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD | DrugsGivenReaction | CC BY-NC | 34716205 | 20,609,820 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral pain'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34716205 | 20,768,929 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD | DrugsGivenReaction | CC BY-NC | 34716205 | 20,609,820 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stomatitis'. | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | IMIQUIMOD, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34716205 | 20,601,177 | 2021-10 |
What was the administration route of drug 'IMIQUIMOD'? | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | Topical | DrugAdministrationRoute | CC BY-NC | 34716205 | 20,601,177 | 2021-10 |
What was the administration route of drug 'TEMOZOLOMIDE'? | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | Oral | DrugAdministrationRoute | CC BY-NC | 34716205 | 20,195,184 | 2021-10 |
What was the outcome of reaction 'Chills'? | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | Recovered | ReactionOutcome | CC BY-NC | 34716205 | 20,609,820 | 2021-10 |
What was the outcome of reaction 'Fatigue'? | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | Recovered | ReactionOutcome | CC BY-NC | 34716205 | 20,609,820 | 2021-10 |
What was the outcome of reaction 'Gingival bleeding'? | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | Recovered | ReactionOutcome | CC BY-NC | 34716205 | 20,768,929 | 2021-10 |
What was the outcome of reaction 'Oral pain'? | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite mu... | Recovered | ReactionOutcome | CC BY-NC | 34716205 | 20,768,929 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34716288 | 20,072,145 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fungaemia'. | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34716288 | 20,099,180 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Herpes simplex'. | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | AMIODARONE, METHYLPREDNISOLONE, OXYGEN | DrugsGivenReaction | CC BY-NC-ND | 34716288 | 20,066,688 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | ACYCLOVIR, CASPOFUNGIN, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34716288 | 20,124,988 | 2021-10-30 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.